Neoadjuvant chemoradiotherapy followed by surgery is the mainstay treatment for locally advanced rectal cancer, leading to significant decrease in tumor size (downsizing) and a shift towards earlier disease stage (downstaging). Extensive histopathological work-up of the tumor specimen after surgery including tumor regression grading and lymph node status helped to visualize individual tumor sensitivity to chemoradiotherapy, retrospectively. As the response to neoadjuvant chemoradiotherapy is heterogeneous, however, valid biomarkers are needed to monitor tumor response. A relevant number of studies aimed to identify molecular markers retrieved from tumor tissue while the relevance of blood-based biomarkers is less stringent assessed. MicroRNAs are currently under investigation to serve as blood-based biomarkers. To date, no screening approach to identify relevant miRNAs as biomarkers in blood of patients with rectal cancer was undertaken. The aim of the study is to investigate the role of circulating miRNAs as biomarkers in those patients included in the TiMiSNAR Trial (NCT03465982). This is a biomolecular substudy of TiMiSNAR Trial (NCT03962088).
Expression levels of circulating miRNAs as biomarkers during multimodal treatment of rectal cancer - TiMiSNAR-mirna: a substudy of the TiMiSNAR Trial (NCT03962088) / Monsellato, Igor; Garibaldi, Elisabetta; Cassinotti, Elisa; Baldari, Ludovica; Boni, Luigi; Elmore, Ugo; Delpini, Roberto; Rosati, Riccardo; Perinotti, Roberto; Alongi, Filippo; Bertocchi, Elisa; Gori, Stefania; Ruffo, Giacomo; Pernazza, Graziano; Pulighe, Fabio; De Nisco, Carlo; Morpurgo, Emilio; Contardo, Tania; Mammano, Enzo; Perna, Federico; Menegatti, Benedetta; Coratti, Andrea; Buccianti, Piero; Balestri, Riccardo; Ceccarelli, Cristina; Cavaliere, Davide; Solaini, Leonardo; Ercolani, Giorgio; Traverso, Elena; Fusco, Vittorio; Torri, Valter; Orecchia, Sara. - In: TRIALS. - ISSN 1745-6215. - 21:1(2020), pp. 678-684. [10.1186/s13063-020-04568-9]
Expression levels of circulating miRNAs as biomarkers during multimodal treatment of rectal cancer - TiMiSNAR-mirna: a substudy of the TiMiSNAR Trial (NCT03962088)
Elmore, Ugo;Delpini, Roberto;Rosati, Riccardo;
2020-01-01
Abstract
Neoadjuvant chemoradiotherapy followed by surgery is the mainstay treatment for locally advanced rectal cancer, leading to significant decrease in tumor size (downsizing) and a shift towards earlier disease stage (downstaging). Extensive histopathological work-up of the tumor specimen after surgery including tumor regression grading and lymph node status helped to visualize individual tumor sensitivity to chemoradiotherapy, retrospectively. As the response to neoadjuvant chemoradiotherapy is heterogeneous, however, valid biomarkers are needed to monitor tumor response. A relevant number of studies aimed to identify molecular markers retrieved from tumor tissue while the relevance of blood-based biomarkers is less stringent assessed. MicroRNAs are currently under investigation to serve as blood-based biomarkers. To date, no screening approach to identify relevant miRNAs as biomarkers in blood of patients with rectal cancer was undertaken. The aim of the study is to investigate the role of circulating miRNAs as biomarkers in those patients included in the TiMiSNAR Trial (NCT03465982). This is a biomolecular substudy of TiMiSNAR Trial (NCT03962088).File | Dimensione | Formato | |
---|---|---|---|
1.pdf
accesso aperto
Tipologia:
PDF editoriale (versione pubblicata dall'editore)
Licenza:
Creative commons
Dimensione
716.06 kB
Formato
Adobe PDF
|
716.06 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.